Abay Pharma Competitors

Abdi İbrahim, Turkish pharmaceutical industry leader, was founded in 1912 in Küçükmustafapaşa, Istanbul at a small pharmacy, by Pharmacist Abdi İbrahim Bey who had started the “healing” journey. Abdi İbrahim has the largest product portfolio in the sector, with nearly 250 brands and more than 500 products which it develops itself as well as working with 30 licensors. With a powerful vision, dynamic structure and contemporary outlook, Abdi İbrahim has been the leader of Turkey’s Pharmaceutical Industry since 2002. Today, Abdi İbrahim, which operates in 19 countries outside Turkey, exports to more than 70 countries ranging from Canada to European Union member states, from North Africa to Asia and creates the highest employment with nearly 5,800 qualified employees in the Turkish pharmaceutical industry. The company also comes to the fore with its marketing and sales team, which is the largest in the industry. Abdi İbrahim, having the first accredited R&D center in the industry, is a role model with its technological equipment and architecture as well as R&D processes in healing the future. Abdi Ibrahim has an R&D Center, production facility for chemical products, Türkiye's largest biotechnological manufacturing facility AbdiBio and hormone production area, ophthalmology production area which will be operational in 2019 and Sterile Injectable & Oncology production facility which will be operational in 2021 in Istanbul Esenyurt production complex. Abdi İbrahim has also R&D Centers and production facilities in Kazakhstan and Algeria. Abdi İbrahim has taken an important step by signing United Nations Global Principles Agreement in 2010 and given the opportunity to share high standards which it has acquired in the fields of human rights, as well as environmental and social responsibility. Besides, Abdi İbrahim has focused its activities on sustainability studies on level A of Global Reporting Initiative (GRI) and published its third Sustainability Report.

The Acıbadem Healthcare Group is Turkey’s most valuable private healthcare organisation according to brand assessment results and the position the group has achieved in the sector. Today Acıbadem, with its 25 hospitals, 15 outpatient clinics, 3.829 doctors and 5.469 nurses, provides healthcare services with nearly 26.440 employees. The Group provides diagnosis and treatment services at certified healthcare standards with a qualified staff, advanced technology, modern infrastructure and JCI accreditation. The journey of growth and development for Acıbadem, which started out as a district hospital in 1991, continues on the world stage with an agreement made in 2012 with IHH Healthcare Berhad, one of the largest groups in the Far East. IHH Healthcare Berhad, which has education and real estate investments in many countries throughout the world in addition to investments in hospitals and healthcare institutions in 8 large countries of the Asian Pacific, is the 2nd largest healthcare chain in the world with a powerful structure comprised of the Malaysian government’s investment fund Khazanah, Japan’s Mitsui & Co. Ltd. and the Aydınlar Family Partnership. In 2016, Acıbadem Healthcare Group acquired the Tokuda Group and the City Clinic Group, both of which are leading Bulgarian healthcare providers. An investment of 125 million Euros enabled Acıbadem to expand its operations by 4 hospitals and 5 outpatient clinics thus making it the largest private healthcare provider in Bulgaria. Acıbadem currently operates 25 hospitals and 15 clinics in 5 countries. The Acıbadem Healthcare Group, provides integrated premium healthcare services with Acıbadem Project Management (Hospital Design, Project Management), APlus (Hospital Hospitality Company), Labmed (Advanced Clinical Lab Company) and Acıbadem Mobile (Mobile Healthcare Services, such as Air & Groud Ambulance).

1958 yılında kurulan DEVA Holding, Türkiye’nin en köklü ve kapsamlı ilaç üreticilerinden biridir. Beşeri ilaçlar, etkin madde, veteriner ürünleri ve tıbbi ampul üretimi gerçekleştiren DEVA; onkolojiden kardiyolojiye, solunum sisteminden oftalmolojiye kadar 15 terapötik alanda 675'ten fazla ürünüyle faaliyet göstermektedir. Ar-Ge merkezi DEVARGE ve Avrupa GMP ile US FDA onaylı üretim tesisleri sayesinde yüksek kalite standartlarında üretim gerçekleştiren DEVA, aralarında ABD, Almanya ve İsviçre gibi ülkelerin de bulunduğu 80'den fazla ülkede ürün ruhsatına sahiptir. Yıllık 620 milyon kutu üretim kapasitesiyle Çerkezköy ve Kartepe’de üretim yapan DEVA, sürdürülebilir bir gelecek için toplum sağlığı, çevre ve eğitim alanlarında sosyal sorumluluk projelerine de katkı sağlamaktadır.